M&T Bank Corp Acquires New Stakes in Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

0

M&T Bank Corp has acquired a new stake in Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) during the first quarter, according to the company in its latest filing with the Securities & Exchange Commission. The institutional investor purchased 6,040 shares of the company, valued at approximately $204,000.

A number of other large investors have also recently bought and sold shares of FMS. Commonwealth Equity Services LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 6.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 13,583 shares of the company worth $440,000 after buying 817 additional shares last quarter. Yousif Capital Management LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q4 for a value of approximately $295,000. Northwestern Mutual Wealth Management Co. increased its position in Fresenius Medical Care AG & Co. KGaA by 223.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,976 shares of the company worth $129,000 after buying 2,745 additional shares last quarter. Advisor Group Holdings Inc. increased its position in Fresenius Medical Care AG & Co. KGaA by 84.4% in the 4th quarter. Advisor Group Holdings Inc. now owns 19,083 shares of the company worth $620,000 after buying 8,737 additional shares in the last quarter. Finally, First Trust Advisors LP strengthened its position in Fresenius Medical Care AG & Co. KGaA by 15.1% in the 4th quarter. First Trust Advisors LP now owns 1,925,326 shares of the company worth $62,496,000 after purchasing an additional 252,768 shares in the last quarter. Hedge funds and other institutional investors own 4.73% of the company’s shares.

A Wall Street analyst gives his opinion

FMS has been the subject of several research analyst reports. StockNews.com downgraded Fresenius Medical Care AG & Co. KGaA from a “strong buy” rating to a “buy” rating in a Friday, July 15 research note. Truist Financial cut its price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a Wednesday, June 22 research note. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research note. JPMorgan Chase & Co. cut its price target on Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a Monday 1st research note august. Finally, Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and raised its price target for the company from $30.30 to $33.70. in a Monday, June 27 research note. One research analyst gave the stock a sell rating, seven gave the company a hold rating and four gave the company a buy rating. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of “Hold” and an average price target of $45.83.

Fresenius Medical Care AG & Co. KGaA Stock down 1.3%

Shares of FMS opened at $18.16 on Friday. The company has a market capitalization of $10.64 billion, a PE ratio of 11.57, a growth price-earnings ratio of 0.93 and a beta of 1.02. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47. Fresenius Medical Care AG & Co. KGaA has a 52-week minimum of $18.05 and a 52-week maximum of $40.45. The stock has a fifty-day simple moving average of $22.50 and a two-hundred-day simple moving average of $28.69.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Featured articles

Institutional ownership by quarter for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.